Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indazole-Cl
- Development stage
- Preclinical
- Lead developer
- Katzenellenbogen Group
- Modality
- Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Indazole-Cl, also known by its chemical name 3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol, is a synthetic small molecule characterized by a phenyl-2H-indazole core. It functions as an estrogen receptor-β (ER-β) agonist. Developed by the Katzenellenbogen group, this nonsteroidal compound has demonstrated efficacy in preclinical studies for preventing atherosclerosis through the activation of ER-β.
- Other names
- 3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol848142-62-1DTXSID40463812DTXSID-40463812DTXSID 40463812RefChem:93386
02
Targets
ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on Indazole-Cl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indazole-Cl.